Nuvectis Pharma, Inc. NVCT Business Segments — Clinical Trial Expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Nuvectis Pharma, Inc. in its filing.
Tagged under the XBRL concept nvct:ClinicalTrialExpenses.
The official record: Nuvectis Pharma, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvectis Pharma, Inc.'s business segments — clinical trial expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvectis Pharma, Inc.'s business segments — clinical trial expenses?
- Nuvectis Pharma, Inc. (NVCT) reported business segments — clinical trial expenses of $1.21M in Q1 2026.
- How has Nuvectis Pharma, Inc.'s business segments — clinical trial expenses changed year-over-year?
- Nuvectis Pharma, Inc.'s business segments — clinical trial expenses increased by 17.0% year-over-year, from $1.04M to $1.21M.
- What is the long-term trend for Nuvectis Pharma, Inc.'s business segments — clinical trial expenses?
- Over 2 years (2023 to 2025), Nuvectis Pharma, Inc.'s business segments — clinical trial expenses has grown at a 12.7% compound annual growth rate (CAGR), from $4.3M to $5.46M.
- What does business segments — clinical trial expenses mean?
- Costs incurred for conducting clinical trials, including patient recruitment, site management, and data monitoring services. This is a primary indicator of the intensity and stage of the company's research and development efforts.